Insilico Medicine Receives Company of the Year Award at BioCentury-BayHelix East-West Summit

Insilico Medicine was named Company of the Year at the East-West BioCentury-BayHelix Summit on November 15. focuses on the globalization of drug discovery and development, as well as cross-border collaborations between East and West.

Insilico Medicine’s Chief Commercial Officer, Michelle Chen, PhD, accepted the award on behalf of the company. “Global partnerships are key to accelerating AI-based drug discovery,” she said. “This year, we entered into a number of strategic collaboration agreements, including a recent agreement with Sanofi, one with EQRx and one with Fosun Pharma. As more and more drug candidates in our pipeline mature, we look forward to what the new year will bring in terms of international collaborations. Dr. Chen presenting at the Biomarker Technologies and AI-Guided Discovery Track and the Biopharma AI Scorecard panel at the BioCentury-BayHelix event.

“Insilico Medicine received several awards this year from leading industry bodies, indicating rapid growth and a substantial acceleration of the company’s R&D,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico. Medical. “However, we are especially thrilled to be named Company of the Year by BioCentury-BayHelix, as Insilico Medicine has participated in numerous BioCentury events with other companies in our field, and we are the only drug discovery company End-to-end AI to get this award as the industry consolidates around a few rapidly growing players.

While Zhavoronkov leads the company’s AI innovation, co-CEO Feng Ren, PhD, who has held leadership positions at GSK and Medicilion, leads the company’s drug discovery and development efforts. Insilico Medicine has extended both its AI capabilities and internal pipeline through the strength of its end-to-end AI platform for target discovery, drug design and clinical trial prediction known as name of Pharma.AI. There are more than 30 drugs in Insilico’s pipeline, including for cancer, fibrosis, central nervous system diseases and COVID-19, and its lead AI-discovered and engineered drug for idiopathic pulmonary fibrosis is currently in phase 1 testing.

“We are honored by this recognition and committed to advancing scientific collaboration to bring new therapies to patients who need them,” said Dr. Ren. “As a truly global company, Insilico Medicine works with partners in AI software, drug discovery, clinical trials and robotics in regional centers of technical and pharmaceutical expertise around the world.”

About Insilico Medicine

Insilico Medicine, an end-to-end clinical-stage artificial intelligence (AI)-focused drug discovery company, connects clinical trial biology, chemistry and analytics using novel AI systems. generation. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover new targets and design new molecular structures with desired properties. Insilico Medicine offers breakthrough solutions to discover and develop innovative drugs against cancer, fibrosis, immunity, central nervous system (CNS) diseases and age-related diseases. Based in Hong Kong, Insilico Medicine has additional offices in Shanghai, Suzhou, Taipei, New York, Montreal and Abu Dhabi.

For more information, visit www.insilico.com

For media inquiries, please contact media@insilicomedicine.com

For business development, please contact bd@insilicomedicine.com